HILYSENS II has its basis on the development and innovation of three major components that will be integrated in the final kit.
The antigens - Peptides from different components of Borrelia during different parts of the disease cycle were chosen for inclusion in the lab-on-a-chip, so as to optimize the test for Borrelia infection.
The tested antigens provide a total sensitivity of almost 100% in the diagnosis of Borrelia infection. The inclusion of bacterial lysates and antigens other than the "classical" ones (in commercial ELISA kits) increase the test sensitivity.
Moreover, the antigens selected for the detection of possible coinfections are useful for babesiosis and ehrlichiosis diagnosis.
The Lyme card chip - the lab-on-a-chip technology permits robust and automatic sample processing and detection in a single step, combined with very specific antigenic proteins and peptides that will be detected by quantum dots (QD) technology due to its excellent properties in terms of enhanced signal to background detection and performance in multiplexed assays.
The Reader - A new fluorescent read-out device was developed to read the Lyme card chip cartridge, enabling the detection and quantification of the QD signals from the different antigen spots located in the detection chamber of the chip.
The Reader incorporates a signal processing and evaluation algorithm together with a user-friendly software interface for simple and unambiguous interpretation of the test results.